[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603545":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":30,"locations":36,"responsibleParty":52,"collaborators":11,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":11,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":11,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":39,"whyStopped":11,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Ausper Biopharma Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Relevant drug treatment group","EXPERIMENTAL",null,[13],"Drug: AHB-137",{"label":15,"type":10,"description":11,"interventionNames":16},"No relevant drug treatment group",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","AHB-137","AHB-137 will be injected",[15,9],[24,28],{"name":25,"affiliation":26,"role":27},"Junqi Niu","The First Hospital of Jilin University","PRINCIPAL_INVESTIGATOR",{"name":29,"affiliation":26,"role":27},"Yanhua Ding",[31],{"name":32,"role":33,"phone":34,"phoneExt":11,"email":35},"Lu","CONTACT","0571-86959519","clinicaltrial@ausperbio.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":11,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"AusperBio Investigational Site","RECRUITING","Jilin City","Changchun","China","CN",{"type":45,"coordinates":46},"Point",[47,48],126.5608,43.84652,{"lat":48,"lon":47},[51],{"name":32,"role":33,"phone":34,"phoneExt":11,"email":35},{"type":53,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100603545","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-ahb-137-injection-in-participants-with-chronic-hepatitis-b-chb-100603545",false,"NCT07137910","A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)","An Open-label, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B Previously Treated With Nucleos (t) Ide Analogues (NA)","Inclusion Criteria:\n\n* Voluntarily participate in the study and sign the informed consent form;\n* 18-65 years of age (including boundary values) ;\n* Body mass index met the requirements;\n* Participants with CHB who are HBsAg or HBV DNA positive for at least 6 months;\n* Meet the relevant requirements for prior medications;\n* HBsAg and HBV DNA and liver function indicators meet the requirements;\n* Effective contraception as required;\n\nExclusion Criteria:\n\n* Uncontrolled and stable clinically significant abnormalities other than a history of CHB infection;\n* Associated liver disease;\n* Any serious infection other than CHB infection requires intravenous anti-infective therapy;\n* HCV RNA positive, HIV antibody positive, syphilis positive;\n* Abnormal laboratory results;\n* Diseases associated with vascular inflammatory conditions;\n* QT interval corrected heart rate (Fridericia method) abnormal;\n* History of malignancy or ongoing assessment of possible malignancy;\n* History of allergies, or allergic constitution;\n* Participants with recent major trauma or major surgery, or planning surgery;\n* Those who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study;\n* Prior\u002Fcurrent use of prohibited medications;\n* Inappropriate for participation in this trial as judged by the investigator.","ALL","18 Years","65 Years",{"count":65,"type":66},60,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","This study is an open-label, multicenter phase II clinical study to evaluate the efficacy and safety of AHB-137 injection in participants with CHB previously treated with NA.",[72],"Chronic Hepatitis B",[74],"Hepatitis B, Chronic","2026-05-01",{"date":77,"type":78},"2026-05-04","ACTUAL",{"date":80,"type":78},"2025-09-04",{"date":82,"type":66},"2027-06-01",{"name":5,"class":6},1]